Oncology

109 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.  

In 1986, muromonab-CD3 (OKT3) wins the first therapeutic monoclonal antibody approval from the US FDA, which works as an immunosuppressive...

Small- molecule kinase inhibitors have the potential for broad efficacy, convenience and tissue penetrance, and thus often offer important advantages...

First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...

Takeda Oncology (Millennium Pharmaceuticals, Inc) is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, developing therapies for the treatment...

Boehringer Ingelheim is a research-driven company operating worldwide under two divisions: Human Pharmaceuticals and Animal Healthcare. In oncology,  Boehringer Ingelheim...

GlaxoSmithKline (GSK) is a global pharmaceutical company with a diversified portfolio of biologics, small molecules and consumer healthcare products. In...

GlaxoSmithKline (GSK) is a global pharmaceutical company with a diversified portfolio of biologics, small molecules and consumer healthcare products. In...